Early trial aims to tame tough blood cancer with novel drug mix
NCT ID NCT05560399
Summary
This early-phase study is testing a new three-drug combination (iberdomide, elotuzumab, and dexamethasone) for adults with multiple myeloma that has come back or stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see how well the treatment works against the cancer. Researchers will also study how the treatment affects the body's immune system to learn which patients might benefit most in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.